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BID. Veliparib Cmax and AUC were approximately dose 
proportional. Six partial responses were observed.
Conclusions Veliparib PK was not impacted by carbopl-
atin and paclitaxel. The safety profile was manageable. The 
120 mg BID RPTD confirmed in Japanese patients is the 
dose being evaluated in global studies of veliparib. Prelimi-
nary efficacy suggests veliparib may enhance carboplatin 
and paclitaxel activity, providing benefit to patients with 
NSCLC.
Keywords Veliparib (ABT-888) · NSCLC · PARP · 
Carboplatin · Paclitaxel
Abbreviations
AE  Adverse event
ALT  Alanine transaminase
AST  Aspartate transaminase
AUC  Area under the curve
BID  Bis in die; two times a day
CI  Confidence interval
CT  Computed tomography
DNA  Deoxyribonucleic acid
DLT  Dose-limiting toxicity
EGFR  Epidermal growth factor receptor
GOG  Gynecologic Oncology Group
HBsAg  Hepatitis B surface antigen
HCV  Hepatitis C virus
HIV  Human immunodeficiency virus
HR  Hazard ratio
LCMS  Liquid chromatography mass spectrometry
MedDRA  Medical dictionary for regulatory activities
NSCLC  Non-small cell lung cancer
OS  Overall survival
PARP  Poly (ADP-ribose) polymerase
PBMC  Peripheral blood mononuclear cell
Abstact 
Introduction Veliparib is a potent, orally bioavailable 
PARP inhibitor that enhances efficacy of DNA-damaging 
chemotherapeutic agents. The study objectives were to 
determine the recommended phase 2 dose (RPTD) of veli-
parib plus carboplatin and paclitaxel, and assess pharma-
cokinetics (PK), tolerability, and preliminary efficacy in 
Japanese patients with solid tumors.
Methods Carboplatin (AUC 6 mg/mL min) and paclitaxel 
(200 mg/m2) were administered on day 3 of a 21-day cycle. 
Oral veliparib (40, 80, or 120 mg BID) was administered 
on days 1–7. Patients received ≤6 cycles. Adverse events 
(AEs) were reported using NCI-CTCAE version 4.03, PK 
parameters were analyzed using noncompartmental meth-
ods, and responses were measured by RECIST version 1.1.
Results Twelve patients with non-small cell lung can-
cer (NSCLC) were treated. Common treatment-emergent 
AEs, consistent with toxicities associated with carbopl-
atin and paclitaxel, included leukopenia (100 %), neutro-
penia (100 %), anemia (83 %), thrombocytopenia (75 %), 
increased alanine aminotransferase (67 %), and increased 
aspartate aminotransferase (67 %). Grade 3/4 AEs (in ≥2 
patients) included neutropenia (100 %), leukopenia (33 %), 
anemia (25 %), and hyponatremia (17 %). No AEs led to 
veliparib, carboplatin, or paclitaxel interruption; no DLTs 
were observed. The RPTD was determined to be 120 mg 
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PD-1  Programmed cell death protein 1
PD  Progressive disease
PFS  Progression-free survival
PK  Pharmacokinetic
PR  Partial response
RPTD  Recommended phase 2 dose
SAE  Serious adverse event
SGOT  Serum glutamic oxaloacetic transaminase
SGPT  Serum glutamic pyruvic transaminase
VEGF  Vascular endothelial growth factor receptor
Introduction
Lung cancer is the most common cancer worldwide, with 
approximately 1.8 million new cases diagnosed globally in 
2012 [1]. Patients with metastatic non-small cell lung can-
cer (NSCLC) are often diagnosed at a late stage and have a 
poor prognosis.
Platinum-based chemotherapy regimens, including the 
combination of carboplatin and paclitaxel, remain the current 
standard of care for patients with NSCLC [2–4]. Improv-
ing the efficacy of these regimens is an important priority to 
achieve more active and individualized treatment options and 
improve patient outcomes. Targeted therapies are emerging 
for the treatment of NSCLC, including epidermal growth fac-
tor receptor (EGFR) inhibitors, vascular endothelial growth 
factor receptor (VEGF) inhibitors, and checkpoint inhibitors 
that target the programmed cell death protein 1 (PD-1) path-
way [2, 5]. There has been particular interest in agents that 
can be safely combined with commonly used chemotherapy 
regimens; the VEGF inhibitor bevacizumab has been rec-
ommended for the use with carboplatin and paclitaxel [2]. 
Inhibitors of poly (ADP-ribose) polymerase (PARP) repre-
sent another class of novel agents with potential utility when 
given with the standard of care chemotherapy.
Dysregulation of DNA repair has been associated with 
resistance to platinum-based therapies in patients with 
NSCLC and can negatively impact survival [6, 7]. PARP-1 
and PARP-2 are nuclear enzymes that recognize DNA dam-
age and facilitate DNA damage repair [8, 9]. PARP inhi-
bition leads to unrepaired DNA damage, accumulation of 
platinum-DNA adducts, and increased death of cancer cells 
[10, 11]. When given with platinum-based chemotherapy, 
PARP inhibitors may improve outcomes in patients with 
NSCLC.
Veliparib is a potent, orally bioavailable, selective inhib-
itor of PARP-1 and PARP-2, with in vitro Ki values of 5.2 
and 2.9 nM, respectively [10, 12]. In preclinical lung can-
cer tumor models, veliparib potentiates the effect of plati-
num-based chemotherapy [10, 13].
Veliparib has been safely combined with standard 
doses of carboplatin and paclitaxel in early phase studies 
in patients with advanced solid tumors, including lung 
and breast cancer; the safety profile was similar to that 
observed with carboplatin and paclitaxel alone and prom-
ising anti-tumor activity was observed [14–16]. In patients 
with advanced or metastatic solid tumors, the maximum 
dose of veliparib was 120 mg BID for 7 days in addition 
to standard doses of carboplatin and paclitaxel and the 
RPTD of 100 mg BID was chosen [14]. Higher doses have 
been cleared in other studies: up to 200 mg BID veliparib 
with carboplatin and paclitaxel in patients with triple-neg-
ative breast cancer [17] and up to 150 mg BID and above 
with carboplatin, paclitaxel, and bevacizumab in patients 
with newly diagnosed ovarian cancer (GOG 9923; study 
ongoing).
In a phase 1 dose-escalation study, partial response (PR) 
was observed in 11/68 patients (16 %; 2 lung, 2 breast, 2 
melanoma, 2 urothelial, head and neck, gastric, unknown 
primary), complete response (CR) in 2/68 patients (3 %; 
breast and urothelial), and stable disease in 35/68 patients 
(51 %). In a phase 2 randomized study of patients with 
advanced or metastatic NSCLC, the median progression-
free survival (PFS) was 5.8 months (95 % CI 4.2–6.1) 
for patients treated with veliparib plus carboplatin and 
paclitaxel versus 4.2 months [95 % CI 3.1–5.6; HR 0.71 
(95 % CI 0.50–1.13)] for patients treated with placebo 
plus carboplatin and paclitaxel. Overall survival (OS) was 
11.1 months (95 % CI 8.8–13.4) for patients treated with 
veliparib plus carboplatin and paclitaxel versus 9.1 months 
(95 % CI 5.4–12.3) for patients treated with placebo plus 
carboplatin and paclitaxel [16]. Similarly, results from 
another phase 2 trial (I-SPY 2) demonstrated that for 
patients with triple-negative breast cancer randomized to 
veliparib and carboplatin plus standard neoadjuvant ther-
apy, the estimated pathologic complete response rates were 
52 versus 26 % for patients treated with standard neoadju-
vant therapy alone [15].
The current study evaluated veliparib plus carboplatin and 
paclitaxel in Japanese patients with NSCLC. The primary 
objective of this study was determination of the recommended 
phase 2 dose (RPTD) in a Japanese population; secondary 
objectives were to assess pharmacokinetics of veliparib, car-
boplatin, and paclitaxel, and preliminary anti-tumor activity.
Materials and methods
Study design
This was an open-label, phase 1 study conducted at a single 
site in Japan (NCT01617928). The study was conducted in 
accordance with the International Conference on Harmo-
nization guidelines and the ethical principles of the Dec-
laration of Helsinki. An independent institutional review 
1065Cancer Chemother Pharmacol (2015) 76:1063–1072 
1 3
board approved the study, and all patients provided written 
informed consent.
Patients
Eligible adult patients (≥20 years of age) must have a histo-
logically or cytologically confirmed malignant solid tumor, an 
Eastern Cooperative Oncology Group Performance Status ≤2, 
and be amenable to standard combination chemotherapy of car-
boplatin and paclitaxel. Patients must have received ≤1 prior 
chemotherapy regimen for advanced-stage disease; adjuvant 
chemotherapy ≥2 years prior to enrollment was not counted 
as a prior regimen. Other eligibility criteria included normal 
bone marrow (absolute neutrophil count ≥1500/mcL and 
platelets ≥150,000/mcL), liver (total bilirubin ≤1.5 × insti-
tutional upper limit of normal; AST/SGOT and ALT/SGPT 
≤2.5 × institutional upper limit of normal), and kidney (cre-
atinine within upper normal limit of institution’s normal range 
or creatinine clearance ≥60 mL/min/1.73 m2 for patients with 
creatinine level above institutional normal) function. Men and 
women of childbearing potential had to agree to use adequate 
contraception.
Patients were excluded if they had prior treatment with 
a PARP inhibitor, systemic chemotherapy, or radiotherapy 
within 3 weeks prior to entering the study (or 6 weeks for 
nitrosoureas or mitomycin C), or known history of aller-
gic reactions to carboplatin or cremophor-paclitaxel. Other 
exclusion criteria included toxicities (with the exception 
of alopecia) from prior systemic chemotherapy, radiation 
therapy, or sclerotherapy that had not recovered to less than 
grade 2, uncontrolled intercurrent illness that might impact 
compliance, peripheral neuropathy (>grade 1), history of sei-
zure disorder, evidence of bleeding diathesis, symptomatic 
brain metastasis, or hepatitis B surface antigen (HBsAg) 
positive, HCV antibody positive, or HIV positivity.
Treatment
All patients received veliparib (40, 80, or 120 mg) BID 
orally at intervals of approximately 12 h on days 1–7 of 
each 21-day cycle. The results of previous early phase 
studies of veliparib in combination with standard carbopl-
atin and paclitaxel informed the doses used in this study; 
120 mg BID was pre-specified as the maximum dose based 
on tolerability in other phase 1 studies in patients with 
advanced solid tumors [14–16].
Carboplatin (AUC 6 mg/mL min) and paclitaxel 
(200 mg/m2) were given via intravenous (IV) administra-
tion on day 3. Six cycles of therapy were planned. Patients 
could receive standard supportive care including treatment 
with a pre-medication regimen to reduce severity of hyper-
sensitivity reactions according to the paclitaxel prescribing 
information [18].
Platelets had to be ≥100,000/mcL, and absolute neu-
trophil count had to be ≥1500/mcL before initiation of the 
next cycle of therapy. Treatment could be postponed for up 
to 21 days because of toxicity; longer delays led to discon-
tinuation. A delay in any one component of the regimen 
required delay of all drugs within the regimen.
Assessments
A complete medical history was collected during the 
screening visit, including detailed oncology history. A 
physical examination was performed at all visits (screen-
ing, days 1, 3, 8, and 15).
The safety of veliparib in combination with carboplatin 
and paclitaxel in Japanese patients was assessed by the 
evaluation of study drug exposure, adverse events (AEs), 
serious AEs (SAEs), deaths, laboratory profiles, physical 
examination, and vital signs. All patients who received at 
least one dose of veliparib were included in the safety anal-
ysis. Treatment-emergent AEs were summarized by system 
organ class and preferred term according to the medical 
dictionary for regulatory activities (MedDRA) AE coding 
dictionary and were graded according to the NCI CTCAE 
version 4.03 [19]. AEs were assessed for severity and rela-
tionship with veliparib.
The study followed a dose-escalation scheme whereby 
at least three patients were enrolled to each dose level in 
a stepwise manner, starting with 40 mg. The dose-limiting 
toxicity (DLT) evaluation period was cycle 1. Events were 
considered as DLTs if they were considered associated with 
veliparib (possibly and probably related) and met the fol-
lowing criteria: any grade 4 neutrophil lasting longer than 
7 days, any grade 4 thrombocytopenia (platelet ≤25,000/
mcL), febrile neutropenia (temperature ≥38.3 or ≥38 °C 
sustained over a 1-h period associated with absolute neutro-
phil count of <0.5 × 109/L), any event resulting in delay of 
the next treatment cycle by more than 3 weeks due to toxic-
ity, or any other ≥grade 3 non-hematological toxicity that 
represented at least a two-grade increase from baseline and 
was clinically significant or symptomatic. Other toxicities 
that did not meet the above criteria may be considered as a 
DLT if the toxicities were considered to be associated with 
study treatment and clinically significant. Overall toxicity 
was considered in dose-escalation decisions.
A CT scan of the full chest and abdomen with images 
of the liver and adrenal glands was performed for all tumor 
assessments at screening (within 3 weeks prior to registra-
tion) and at the end of every 2 cycles (6 weeks). Tumor 
assessments were performed within 7 days of the sched-
uled date. Patients who had at least one measurable lesion 
at baseline and who received at least one dose of veli-
parib were evaluated for anti-tumor response criteria using 
RECIST version 1.1 [20].
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Blood samples were collected on days 1 and 3 of cycle 
1 for veliparib pharmacokinetic analysis and on day 3 of 
cycle 1 for paclitaxel and carboplatin pharmacokinetic 
analysis. On days 1 and 3 of cycle 1, blood was collected 
to assay veliparib concentrations before the morning dose 
of veliparib and 0.5, 1, 1.5, 2, 4, 6, and 8 h after dosing. 
On day 3 of cycle 1, blood was collected to assay pacli-
taxel concentrations before administration of the morn-
ing dose of paclitaxel and 1, 2, 3 (immediately after end-
ing paclitaxel infusion), 4, 6, 8, and 24 h after dosing. On 
day 3 of cycle 1, blood was collected to assay carboplatin 
concentrations immediately after ending paclitaxel infusion 
(before beginning carboplatin infusion) and 0.25, 1, 3, 5, 
and 21 h after dosing. On day 3 of cycle 1, veliparib was 
ingested at essentially the same time as paclitaxel infu-
sion began and carboplatin infusion immediately followed 
paclitaxel infusion. Plasma samples were stored at −20 °C 
until shipment to AbbVie. Plasma concentrations of veli-
parib and paclitaxel were determined using validated liquid 
chromatography methods with tandem mass spectrometric 
detection (LCMS/MS). Plasma concentrations of carbopl-
atin were determined using an inductively coupled plasma 
mass spectrometry. Standard pharmacokinetic parameters 
were determined using non-compartmental methods.
Table 1  Patient characteristics 
(safety population)
ECOG Eastern Cooperative Oncology Group
a Days from date of diagnosis to date of first dose of study drug
b Baseline
c At time of enrollment













 Female 0 0 2 2 (17)
 Male 3 3 4 10 (83)
Age, years, median (range) 71 (67–72) 56 (44–60) 67 (47–73) 67 (44–73)
Race, n (%)
 Japanese 3 3 6 12 (100)
Median duration of diseasea (range), days 63 (22–84) 70 (46–77) 62.5 (48–2739) 64 (22–2739)
Histology at time of diagnosis, n (%)
 Adenocarcinoma 1 3 6 10 (83)
 Other 1 0 0 1 (8)
 Not available 1 0 0 1 (8)
ECOG performance statusb, n (%)
 0 1 2 3 6 (50)
 1 2 1 3 6 (50)
Clinical stagec, n (%)
 Stage IIIB 0 0 1 1 (8)
 Stage IV 2 3 4 9 (75)
 Postoperative recurrence 1 0 1 2 (17)
Tumor burdenb, n (%)
 Locally advanced 1 0 1 2 (17)
 Metastatic 2 3 5 10 (83)
Tobacco, n (%)
 Current 0 0 2 2 (17)
 Former 3 3 2 8 (67)
 Never used 0 0 2 2 (17)
Prior oncology surgery 1 0 1 2 (17)
Prior systemic or radiation therapy 0 0 0 0 (0)
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Table 2  Treatment-emergent adverse events
AEs in ≥20% 
of all patients,  
n














All grades Grade  
3/4
All grades Grade  
3/4
All grades Grade 3/4 All grades At least  
possibly related
All grades At least  
possibly 
related
Any AE 3 3 3 3 6 5 12 11 12 11
Blood and lymphatic system disorders
 Anemia 3 1 1 0 6 2 10 9 3 3
 Leukopenia 3 0 3 0 6 4 12 11 4 3
 Neutropenia 3 3 3 3 6 6 12 11 12 11
 Thrombocyto-
penia
2 0 1 0 6 0 9 8 0 0
Gastrointestinal disorders
 Constipation 3 0 0 0 3 0 6 4 0 0
 Diarrhea 1 0 0 0 2 0 3 2 0 0
 Nausea 2 0 2 0 4 0 8 5 0 0
General disorders, admin site conditions











2 0 2 0 4 0 8 8 0 0
Metabolism and nutrition disorders
 Decreased 
appetite
2 0 1 0 5 0 8 6 0 0
 Hypoalbu-
minemia
1 0 0 0 2 0 3 3 0 0
 Hyponatremia 1 1 0 0 2 1 3 1 2 0
Musculoskeletal and connective tissue
 Arthralgia 3 0 2 0 6 0 11 2 0 0








1 0 0 0 4 1 5 1 1 1
Skin and subcutaneous tissue disorders
 Alopecia 1 0 2 0 5 0 8 2 0 0
 Rash 1 0 3 0 0 0 4 4 0 0
Vascular disorders
 Hypertension 0 0 2 1 0 0 2 2 1 1




Twelve patients were enrolled (May 2012–January 2013) 
and received at least one dose of veliparib. All enrolled 
patients had advanced or metastatic non-small cell lung 
cancer (NSCLC). Patient characteristics are summarized in 
Table 1.
Safety
Veliparib plus carboplatin and paclitaxel was well tolerated 
in this population of Japanese patients with NSCLC. AEs 
were consistent with toxicities commonly associated with 
the combination. Treatment-emergent AEs that occurred 
in more than 20 % of patients are summarized in Table 2. 
The majority of AEs were mild to moderate (grade 1 and 
2). The most commonly occurring AEs of any grade (with-
out attribution to veliparib) included leukopenia (n = 12; 
100 %), neutropenia (n = 12; 100 %), arthralgia (n = 11; 
92 %), myalgia (n = 10; 83 %), anemia (n = 10; 83 %), 
and thrombocytopenia (n = 9; 75 %). The most commonly 
occurring grade 3/4 AEs (without attribution to veliparib) 
included neutropenia (n = 12; 100 %), leukopenia (n = 4; 
33 %), and anemia (n = 3; 25 %). Although hematological 
toxicities were commonly observed, these toxicities were 
manageable with medication or dose reductions and delays.
The median number of cycles was 4 (range 1–6). No 
treatment-emergent AEs led to interruption of veliparib, 
carboplatin, or paclitaxel. Three patients (25 %) experi-
enced a treatment-emergent AE that resulted in dose reduc-
tions in veliparib (n = 1 grade 3 hypertension, 80 mg BID 
and n = 2 grade 3 anemia, 120 mg BID). Seven patients 
(58 %) experienced a treatment-emergent AE that led to 
dose delays in veliparib, carboplatin, or paclitaxel. Two 
Table 3  Mean ± SD 
pharmacokinetic parameters 
after administration of 
veliparib with and without 
carboplatin + paclitaxel
a Veliparib administered orally BID on days 1 through 7; carboplatin (AUC 6 mg/mL min) and paclitaxel 
(200 mg/m2) administered intravenously on day 3. Based on carboplatin concentrations, the last sampling 
time point was 21 h after starting intravenous infusion of carboplatin








Study day 1 (after veliparib alone)a
 Tmax (h) 2.5 ± 1.3 3.3 ± 1.2 3.0 ± 1.1 3.0 ± 1.1
 Cmax (ng/mL) 327 ± 47.7 481 ± 27.8 844 ± 152 –
 AUC0–8 (ng h/mL) 1287 ± 370 2137 ± 197 3993 ± 796 –
 AUC∞ (ng h/mL) 1838 ± 671 2804 ± 266 5757 ± 1166 –
 Cmax/dose, (ng/mL)/mg 8.18 ± 1.19 6.01 ± 0.35 7.03 ± 1.27 7.06 ± 1.29
 AUC0–8/dose (ng h/mL)/mg 32.2 ± 9.24 26.7 ± 2.46 33.3 ± 6.34 31.4 ± 6.69
 AUC∞/dose (ng h/mL)/mg 46.0 ± 16.8 35.0 ± 3.33 48.0 ± 9.72 44.2 ± 11.3
Study day 3 (after carboplatin + paclitaxel)a
 Tmax (h) 2.5 ± 1.3 4.0 ± 0.0 1.4 ± 0.5 2.3 ± 1.3
 Cmax (ng/mL) 345 ± 149 400 ± 48.8 1245 ± 149 –
 AUC0–8 (ng h/mL) 1511 ± 457 2157 ± 48.3 5007 ± 960 –
 AUC0–12 (ng h/mL) 1929 ± 572 2781 ± 94.5 6246 ± 1054 –
 Cmax/dose, (ng/mL)/mg 8.63 ± 3.73 5.00 ± 0.61 10.4 ± 1.24 8.60 ± 2.92
 AUC0–8/dose (ng h/mL)/mg 37.8 ± 11.4 27.0 ± 0.60 41.7 ± 8.00 37.0 ± 9.63
 AUC0–12/dose (ng h/mL)/mg 48.2 ± 14.3 34.8 ± 1.18 52.0 ± 8.78 46.8 ± 11.3
Carboplatin PK parameters (units)
 Tmax (h) 1.0 ± 0.0 1.0 ± 0.0 1.0 ± 0.0 1.0 ± 0.0
 Cmax (µg/mL) 22.3 ± 2.37 24.3 ± 1.16 22.0 ± 2.45 22.6 ± 2.25
 AUC∞ (µg h/mL) 105 ± 12.3 105 ± 7.14 100 ± 5.73 103 ± 7.67
 AUCt (µg h/mL) 94.1 ± 9.91 95.1 ± 5.83 90.3 ± 5.45 92.5 ± 6.54
Paclitaxel PK parameters (units)
 Tmax (h) 3.1 ± 0.2 3.0 ± 0.0 2.7 ± 0.4 2.9 ± 0.3
 Cmax (µg/mL) 7.56 ± 0.48 6.40 ± 1.22 6.69 ± 1.43 6.84 ± 1.20
 AUC∞ (µg h/mL) 27.2 ± 0.23 22.8 ± 2.37 25.9 ± 3.16 25.5 ± 2.89
 AUCt (µg h/mL) 26.4 ± 0.30 22.1 ± 2.44 25.3 ± 3.09 24.8 ± 2.86
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patients experienced an AE of peripheral sensory neuropa-
thy that led to discontinuation (n = 1 grade 2 event begin-
ning on day 79 and continuing as of day 100 and n = 1 
grade 3 event beginning on day 48 and continuing as of day 
78). There were no SAEs or AEs that led to death. There 
were no DLTs at any dose level during the DLT assessment 
period. There were no clinically relevant changes in labo-
ratory chemistries, urinalysis, or vital signs. The RPTD of 
veliparib administered with carboplatin and paclitaxel was 
determined to be 120 mg BID.
Pharmacokinetics
Pharmacokinetic parameters are summarized in Table 3. 
Veliparib Cmax and AUC values were approximately dose 
proportional at the three dose levels of veliparib (40, 80, 
and 120 mg). For each dose of veliparib, maximum plasma 
veliparib concentrations were observed approximately 
Fig. 1  Greatest percent decrease from baseline in the sum of tumor 
sizes of target lesions assessed by investigator (efficacy population). 
For 9 patients, the greatest percent decrease from baseline in the sum 
of target lesions occurred following completion of 6 cycles of the 
combination regimen. One patient (40 mg BID) achieved the great-
est percent decrease from baseline in cycle 4 (indicated by #). One 
patient (120 mg BID) achieved the greatest percent decrease from 
baseline in cycle 2 (indicated by *)
Fig. 2  Partial response to veli-
parib 40 mg BID and carbopl-
atin and paclitaxel. CT images 
at baseline (a, c) and following 
treatment (15 weeks; b, d) in an 
approximately 70-year-old male 
with advanced NSCLC
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2–3 h after administration. Co-administration of carbopl-
atin and paclitaxel had no significant effect on veliparib 
Tmax, dose-normalized Cmax, or dose-normalized AUC 
(p ≥ 0.2377; Table 3). Carboplatin and paclitaxel pharma-
cokinetics were comparable when co-administered with 40, 
80, or 120 mg veliparib BID, respectively, showing no evi-
dence of an effect of veliparib on carboplatin or paclitaxel 
pharmacokinetics (Table 3).
Efficacy
Eleven patients had at least one measurable lesion at base-
line and comprised the efficacy analysis population. The 
overall response rate was 55 % (6/11 patients, 95 % CI 
23.4–83.3 %). Six patients achieved a PR (n = 2, 40 mg BID 
and n = 4, 120 mg BID); of these, 3 achieved PR at the first 
CT scan. Four patients achieved stable disease (SD) (n = 2, 
80 mg BID and n = 2, 120 mg BID). One (80 mg BID) 
developed progressive disease (PD). The median PFS was 
92 days (range 21–143). The best percent change from base-
line in the sum of target lesions is presented in Fig. 1. The 
greatest percent decrease from baseline in the sum of target 
lesions occurred in cycle 4 for 1 patient (40 mg BID) and in 
cycle 2 for 1 patient (120 mg BID). For all other patients, 
the greatest percent decrease from baseline in the sum of 
target lesions occurred following completion of the combi-
nation regimen. Figure 2 shows a CT image at baseline and 
following treatment in a patient with advanced NSCLC who 
achieved a PR following treatment (40 mg BID).
Discussion
The current study established the safety and tolerability 
of veliparib up to 120 mg BID in combination with car-
boplatin AUC 6 and paclitaxel 200 mg/m2 every 3 weeks 
in Japanese patients with NSCLC. The AEs that occurred 
were similar to those expected with the carboplatin and 
paclitaxel regimen alone [21]. Hematological toxicities 
were common and included neutropenia, anemia, thrombo-
cytopenia, and leukopenia. These toxicities were generally 
managed with medication or dose reductions or delays. The 
RPTD of veliparib in combination with carboplatin and 
paclitaxel was determined to be 120 mg BID.
The doses used in the current study were expected 
to be biologically active. Results of a previous phase 0 
study showed substantial inhibition of PARP activity in 
tumor biopsies collected 3–6 h after dosing in 3 subjects 
who received a single dose of 25 mg veliparib (92, 95, 
and 100 %) [22]. Complete inhibition of PARP activity 
in PBMCs was achieved and maintained for 24 h in 3 of 
those who received 50 mg veliparib. For the 50-mg group, 
PARP inhibition in tumor biopsies averaged 75 % 3–6 h 
after dosing (N = 3) and 74 % 24 h after dosing (N = 3). 
Therefore, both 25 mg and 50 mg veliparib were found to 
be biologically active doses [22]; thus, the doses of 40 mg 
BID or greater used in the phase 1 study could contribute to 
observed activity.
As expected, administration of carboplatin and pacli-
taxel in combination with veliparib did not impact the 
pharmacokinetic profile of veliparib. Veliparib is a highly 
soluble and permeable compound. It is primarily elimi-
nated by renal excretion and to a lesser extent by mul-
tiple cytochrome P450 enzymes in humans and is not an 
inhibitor of major cytochrome P450 enzymes or major drug 
transporters at therapeutic doses [23]. Veliparib pharma-
cokinetic parameters were approximately dose proportional 
at the dose levels evaluated (40, 80, 120 mg BID). Effects 
of veliparib on carboplatin and paclitaxel were evaluated 
indirectly by comparing the carboplatin or paclitaxel phar-
macokinetic profiles following co-administration veliparib 
(40, 80, or 120 mg BID). Although the comparisons do 
not provide definitive evidence, the findings were consist-
ent with expectation of no pharmacokinetic interaction 
between veliparib and carboplatin or paclitaxel. Consist-
ent with the physicochemical property and the elimination 
pathways of veliparib, the pharmacokinetic profile of veli-
parib also was generally comparable between Japanese and 
Western populations.
The sample size of the current study was sufficient to 
investigate pharmacokinetics and identify an appropriate 
RPTD. Patients with histologically or cytologically con-
firmed malignant solid tumors were eligible for this study 
as long as they received only ≤1 prior chemotherapy regi-
men. Despite these selection criteria, all of the patients 
enrolled in the current study were patients with NSCLC. 
The overall response rate was 55 %. As the primary objec-
tives were safety and pharmacokinetic assessment, tumor 
assessment data were not collected after completing study 
treatment. As a result, only 4 subjects had a final tumor 
assessment with PD and the remaining 8 subjects were cen-
sored without documented PD; the estimated median PFS 
is 92 days.
PARP inhibitors are believed to be particularly effec-
tive in tumors with defects in homologous recombination 
such as those with BRCA mutation. The results of this 
trial suggest that veliparib may be effective and improve 
sensitivity to chemotherapy in tumors without identified 
defects in DNA repair, including NSCLC. In addition, in 
a recently reported placebo-controlled phase 2 trial in 
advanced NSCLC, a trend toward improved PFS and OS 
was observed when veliparib was added to carboplatin and 
paclitaxel [16]. Veliparib has also shown preliminary effi-
cacy in other solid tumor types, including triple-negative 
breast, head and neck, and ovarian cancers [14, 17]. Given 
the limited heterogeneity in this phase 1 study, further 
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study in other solid tumor types is warranted. Future larger-
scale studies will be useful to verify efficacy in these tumor 
types.
Conclusions
The current study established tolerability of the addition 
of veliparib to platinum-based chemotherapy. The RPTD 
of veliparib administered with carboplatin and paclitaxel 
in Japanese patients was determined to be 120 mg BID. 
An overall response rate of 55 % warrants future studies. 
Future studies are examining veliparib at this dose, alone 
and in combination with carboplatin and paclitaxel, in 
patients with advanced NSCLC and other solid tumors.
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